Rheumatoid Arthritis (RA) is an autoimmune disorder affecting up to 1% of the population, associated with significant morbidity and mortality if not treated aggressively. Justifiably, it has been a target of great interest to biotech and pharma companies because, although there are now many drugs available, no one single drug or class of drug is universally effective and all have toxicities that can limit their use.

Download our brochure to learn more about PharmaLegacy’s arthritis models and how NHPs can deliver more clinically relevant results.